Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Supporting the Safe, Effective and Efficient Use of UV-C Disinfection in Healthcare and Beyond

UV-C light has been part of disinfection processes in healthcare settings for some time. Now, it’s becoming an essential tool in other environments as a safe and fast way to kill pathogens. But using UV-C effectively requires users to know if they’ve delivered a sufficient dose of irradiation to a variety of surfaces – and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Supporting the Safe, Effective and Efficient Use of UV-C Disinfection in Healthcare and Beyond

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

UV-C light has been part of disinfection processes in healthcare settings for some time. Now, it’s becoming an essential tool in other environments as a safe and fast way to kill pathogens. But using UV-C effectively requires users to know if they’ve delivered a sufficient dose of irradiation to a variety of surfaces – and that can be difficult because UV-C is, in practical terms, an invisible tool.

Since the beginning of the pandemic, the world is acutely aware that infection control isn’t just for hospitals. Discussing these new use cases and how UV-C works, host Daniel Litwin spoke with Wendy Brady, Director of Global Marketing for Intellego Technologies.

“Pathogens are everywhere on the surfaces we touch and the air we breathe. UV-C can be an important tool to protect spaces outside of healthcare,” Brady said. But the key to successful UV-C disinfection is ensuring that you’ve delivered the right amount of ultraviolet irradiation to surfaces.

So, how exactly does UV-C light work?

“UV-C is part of the ultraviolet spectrum and it has a powerful germicidal effect on bacteria, viruses and fungi,” Brady explained. “The way it works is by breaking the DNA or RNA bonds in organisms so they can then no longer reproduce. It renders them inactive, but a sufficient amount of energy or irradiation must be delivered to surface in order to achieve a germicidal effect.”

With established and widespread use in hospitals, other industries are now looking to the technology to help combat pathogens and make public areas safer. Brady said that schools, airports, hotels, event venues, commercial office buildings and more are all beginning to employ different types of UV-C systems to provide a higher level of sanitization.

Because UV-C is often used in unoccupied spaces or in closed cabinet systems, it’s challenging for operators to know if their device is truly working and that all target areas have received enough irradiation to achieve sanitization. It’s not something they can see, but dosimeters provide that important piece of visible evidence.

UVC Dosimeters have a color-changing indicator area that shows the ‘dose’ or how much germicidal irradiation has been delivered. By seeing the dose, measured as 25, 50 or 100 mJ/cm², a person can verify that the device has delivered enough energy needed to kill SARS-CoV-2, MRSA or even C. Difficile,” Brady said.

With a dosimeter, users have accurate, visible confirmation and real-time evidence that a UV-C disinfection device has done its job. With this additional context, disinfecting can become a more efficient process and it builds confidence in the effectiveness of the technology.

“Dosimeters can also save time, as users can see when the disinfection cycle is successful. Operators are finding that some areas can be sanitized more quickly than expected because they can see when they’ve reached a target dose. This means they can use their UV-C equipment in a more efficient manner, sanitizing more areas and creating safer environments,” Brady added.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Direct-to-consumer telehealth raises spending, even as ASC investment surges

Direct-to-consumer telehealth raises spending, even as ASC investment surges

A Health Affairs analysis of commercial claims data (2011–13) found 12% of direct-to-consumer telehealth visits replaced visits to other providers and 88% represented new utilization, with net annual spending on acute respiratory illness increasing $45 per telehealth user. Separately, MobiHealthNews reported on August 31, 2026, via a HIMSSCast episode, that Erik Tellefson of Capital One said ambulatory surgery centers “represent one of the clearest growth structures in American healthcare.”

  • 01The most actionable benchmark for finance teams evaluating DTC telehealth is substitution rate, not visit growth. Health Affairs measured 12% substitution and 88% new utilization in commercial claims for acute respiratory illness.
  • 02The $45 per-user net annual spend increase in the Health Affairs analysis is small enough to hide in PMPM reporting but large enough to matter at scale, and it should be stress-tested against virtual-visit eligibility rules and repeat-use patterns.

Sep 2, 2026

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA named Corewell Health CFO Matthew E. Cox as its national chair effective June 1, 2026, while elevating revenue cycle and reimbursement leaders to its board, according to HFMA’s GlobeNewswire announcement. The association’s own coverage of CMS’s FY 2027 IPPS/LTCH PPS final rule summary and new Medicare cost-reporting requirements such as Worksheet S-12 indicates a compliance workload that is increasingly data- and documentation-heavy for hospital finance and reporting teams. In parallel, HFMA’s certification catalog, including the Certified Hospital Cost Report Specialist (CHCRS) and Certified Specialist Payment & Reimbursement (CSPR), points to how health systems are professionalizing the skill sets needed to operationalize reimbursement policy changes. For operators, the practical consequence shows up in staffing models, audit readiness, and the data plumbing needed to produce defensible cost reports and faster revenue cycle decisions.

  • 01HFMA’s board slate now visibly includes roles that control the work: a system CFO (Corewell Health) and a chief revenue officer overseeing $7 billion in patient revenue at Orlando Health, per GlobeNewswire. That’s a signal that cost reporting and revenue cycle execution are board-level concerns, not back-office chores.
  • 02Medicare cost reporting is moving toward more granular worksheets and documentation, and each new CMS reporting requirement becomes a data-integration project before it becomes a policy memo, per HFMA’s reporting on Worksheet S-12 and its FY 2027 IPPS/LTCH PPS coverage.
  • 03HFMA’s CHCRS, CRCR, and CSPR credentials provide a concrete way to benchmark internal capability: if cost report preparation, managed care contract terms, and prior auth workflows live in different teams, credentialing can reveal where handoffs are breaking down.

Sep 2, 2026

FDA QMSR ties supplier contracts to inspection prep

FDA QMSR ties supplier contracts to inspection prep

FDA’s Quality Management System Regulation (QMSR) took effect Feb. 2, 2026, incorporating ISO 13485:2016 into 21 CFR Part 820 and shifting inspections to a process-based model under Compliance Program 7382.850, according to MD+DI. That change is starting to show up outside the quality department: medical device OEMs are being pushed to spell out documentation, audit support, and change-control responsibilities in contract manufacturing agreements, as Medical Design and Outsourcing described. Two recent partnership moves, Ratio Therapeutics expanding radiopharmaceutical manufacturing with PharmaLogic in Idaho Falls and Menicon shifting U.S. Rose K manufacturing access to three partners after concluding a prior arrangement, illustrate how multi-party supply chains now need contract terms that map directly to integrated QMS evidence. The operational consequence is simple: under CP 7382.850, a complaint, supplier nonconformance, or process change can pull investigators across CAPA, risk management, purchasing, and design records in one thread, so contracts and quality records have to be built to travel together.

  • 01Under FDA CP 7382.850, inspection risk increasingly sits in the “handoffs” between complaint handling, CAPA, supplier controls, and the Risk Management File, so quality evidence has to be assembled end-to-end, not by department.
  • 02For OEMs outsourcing manufacturing, the most useful contract test in 2026 is whether each clause produces inspectable artifacts, who owns them, where they live, and how fast they can be produced during an audit.
  • 03Multi-partner manufacturing models, like Menicon’s three-partner Rose K availability and Ratio’s capacity expansion with PharmaLogic, raise the bar on configuration control, supplier risk classification, and change notification across sites.

Sep 2, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512